Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

TRANEXAMIC ACID IMPURITY D CRS (15 MG)

TRANEXAMIC ACID IMPURITY D CRS (15 MG)

ND

DISCOVER
TESTOSTERONE FOR ID AND ASSAYCRS (90 MG)

TESTOSTERONE FOR ID AND ASSAYCRS (90 MG)

ND

DISCOVER
CLOBETASOL PROPIONATE FOR PEAK IDENTIFICATION CRS (2 MG)

CLOBETASOL PROPIONATE FOR PEAK IDENTIFICATION CRS (2 MG)

ND

DISCOVER
DONEPEZIL FOR SYSTEM SUITABILITY CRS (10 MG)

DONEPEZIL FOR SYSTEM SUITABILITY CRS (10 MG)

ND

DISCOVER
ROSUVASTATIN IMPURITY MIXTURECRS (0.002 MG)

ROSUVASTATIN IMPURITY MIXTURECRS (0.002 MG)

ND

DISCOVER
SULFAMETHIZOLE FOR SYSTEM SUITABILITY CRS (10 MG)

SULFAMETHIZOLE FOR SYSTEM SUITABILITY CRS (10 MG)

ND

DISCOVER
NOMEGESTROL ACETATE IMPURITY B CRS (0.0008 MG)

NOMEGESTROL ACETATE IMPURITY B CRS (0.0008 MG)

ND

DISCOVER
ERGOMETRINE IMPURITY MIXTURE CRS (0.002 MG)

ERGOMETRINE IMPURITY MIXTURE CRS (0.002 MG)

ND

DISCOVER
PROCAINE BENZYLPENICILLIN IMPURITY F CRS (0.025 MG)

PROCAINE BENZYLPENICILLIN IMPURITY F CRS (0.025 MG)

ND

DISCOVER
TILIDINE FOR SYSTEM SUITABILITY CRS - * NARC (TILIDINE HYDRO

TILIDINE FOR SYSTEM SUITABILITY CRS - * NARC (TILIDINE HYDRO

ND

DISCOVER
TILIDINE HYDROCHLORIDE HEMIHYDRATE CRS - * NARC (20 MG)

TILIDINE HYDROCHLORIDE HEMIHYDRATE CRS - * NARC (20 MG)

ND

DISCOVER
TESTOSTERONE FOR SYSTEM SUITABILITY A CRS (20 MG)

TESTOSTERONE FOR SYSTEM SUITABILITY A CRS (20 MG)

ND

DISCOVER